Qiagen (NYSE:QGEN – Get Free Report) was the recipient of a large increase in short interest in September. As of September 15th, there was short interest totalling 3,500,000 shares, an increase of 17.4% from the August 31st total of 2,980,000 shares. Currently, 1.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,220,000 shares, the days-to-cover ratio is currently 2.9 days.
Analysts Set New Price Targets
Several research firms have weighed in on QGEN. Robert W. Baird raised their price target on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Wolfe Research upgraded Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a research report on Thursday, June 27th. Finally, JPMorgan Chase & Co. upped their target price on shares of Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a report on Tuesday, June 18th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Qiagen has an average rating of “Moderate Buy” and an average target price of $50.25.
Read Our Latest Research Report on Qiagen
Institutional Trading of Qiagen
Qiagen Trading Up 0.0 %
QGEN traded up $0.01 during midday trading on Monday, hitting $45.25. The company’s stock had a trading volume of 53,759 shares, compared to its average volume of 1,188,568. The firm has a market cap of $10.33 billion, a P/E ratio of 30.34, a PEG ratio of 3.20 and a beta of 0.39. Qiagen has a 52-week low of $34.74 and a 52-week high of $47.44. The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27. The firm has a 50-day moving average price of $45.20 and a two-hundred day moving average price of $43.48.
Qiagen (NYSE:QGEN – Get Free Report) last released its earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.52 by $0.03. The firm had revenue of $496.00 million during the quarter, compared to the consensus estimate of $495.45 million. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. Qiagen’s revenue was down .2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.53 earnings per share. On average, research analysts anticipate that Qiagen will post 2.15 earnings per share for the current year.
Qiagen Company Profile
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Featured Articles
- Five stocks we like better than Qiagen
- How to Read Stock Charts for Beginners
- Is David Tepper Right About Chinese Stocks?
- What Does Downgrade Mean in Investing?
- Earnings Season Countdown: 4 Stocks Poised for Growth
- Want to Profit on the Downtrend? Downtrends, Explained.
- Salesforce Stock Gets a Wall Street Boost, Cloud Businesses Back?
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.